Antazoline

Antazoline
Clinical data
Trade names	Vasocon-a
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of; administration	Topical (nasal, eye drops)
ATC code	R01AC04 (WHO) R06AX05 (WHO);
Legal status
Legal status	AU: S4 (Prescription only) / Schedule 2;
Identifiers
	IUPAC name N-(4,5-Dihydro-1H-imidazol-2-ylmethyl)-N-(phenylmethyl)aniline;
CAS Number	91-75-8;
PubChem CID	2200;
IUPHAR/BPS	7116;
DrugBank	DB08799;
ChemSpider	2115;
UNII	DHA8014SS1;
KEGG	D07458;
ChEBI	CHEBI:84115;
ChEMBL	ChEMBL1305;
CompTox Dashboard (EPA)	DTXSID3022613 ;
ECHA InfoCard	100.001.904
Chemical and physical data
Formula	C17H19N3
Molar mass	265.360 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES N\1=C(\NCC/1)CN(c2ccccc2)Cc3ccccc3;
	InChI InChI=1S/C17H19N3/c1-3-7-15(8-4-1)13-20(14-17-18-11-12-19-17)16-9-5-2-6-10-16/h1-10H,11-14H2,(H,18,19); Key:REYFJDPCWQRWAA-UHFFFAOYSA-N;

Antazoline is a 1st generation antihistamine with anticholinergic properties used to relieve nasal congestion and in eye drops, usually in combination with naphazoline, to relieve the symptoms of allergic conjunctivitis. To treat allergic conjunctivitis, antazoline can be combined in a solution with tetryzoline. The drug is a Histamine H1 receptor antagonist: selectively binding to but not activating the receptor, thereby blocking the actions of endogenous histamine and subsequently leading to the temporary relief of the negative symptoms brought on by histamine.